Cargando…

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes

Detalles Bibliográficos
Autores principales:	Hyak, Jonathan M., Huang, Ying, Rogers, Kerry A., Bhat, Seema A., Grever, Michael R., Byrd, John C., Kittai, Adam S., Jones, Dan, Miller, Cecelia R., Woyach, Jennifer A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631640/ https://www.ncbi.nlm.nih.gov/pubmed/35834733 http://dx.doi.org/10.1182/bloodadvances.2022007708

Ejemplares similares

Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors
por: Bond, David A, et al.
Publicado: (2020)

Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL
por: Yano, Max, et al.
Publicado: (2022)

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
por: Lew, Thomas E., et al.
Publicado: (2021)

BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL
por: Rogers, Andrew, et al.
Publicado: (2020)

Racial and socioeconomic disparities in CLL/SLL: analysis of SEER data from 2006 to 2019
por: Kittai, Adam S., et al.
Publicado: (2022)

Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review
por: Quartermaine, Cooper, et al.
Publicado: (2023)

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors
por: Thompson, Ella R., et al.
Publicado: (2022)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL
por: Pleyer, Christopher, et al.
Publicado: (2022)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations
por: Lovell, Alexandra R., et al.
Publicado: (2022)

Glabellar and auricular leukemia cutis in CLL
por: Steinman, Bradley, et al.
Publicado: (2022)

Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation
por: Chen, Sunnia T., et al.
Publicado: (2022)

Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
por: Frustaci, Anna Maria, et al.
Publicado: (2023)

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
por: Sharma, Shruti, et al.
Publicado: (2016)

Circulating versus cellular tumor DNA for the detection of BTK resistant CLL clones
por: Trummer, Arne, et al.
Publicado: (2022)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
por: Byrd, John C., et al.
Publicado: (2018)

The Nanomechanical Properties of CLL Cells Are Linked to the Actin Cytoskeleton and Are a Potential Target of BTK Inhibitors
por: Sampietro, Marta, et al.
Publicado: (2023)

Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy
por: Yano, Max, et al.
Publicado: (2022)

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
por: Byrd, John C., et al.
Publicado: (2019)

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
por: Blombery, Piers, et al.
Publicado: (2022)

P623: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022)

P625: A PHASE 1B/2 STUDY OF NAVTEMADLIN COMBINED WITH ACALABRUTINIB IN BTK INHIBITOR NAÏVE PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
por: Byrd, John C., et al.
Publicado: (2023)

Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance
por: St-Pierre, Frédérique, et al.
Publicado: (2022)

S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY
por: Brown, Jennifer R., et al.
Publicado: (2023)

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
por: Chen, Timothy L., et al.
Publicado: (2021)

Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells
por: Shorer Arbel, Yamit, et al.
Publicado: (2021)

Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i
por: Seymour, John F.
Publicado: (2022)

Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis
por: Brem, Elizabeth A., et al.
Publicado: (2022)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma
por: Zent, Clive S., et al.
Publicado: (2020)

P594: THE CXCR4-LOW/CD5-HIGH PROLIFERATIVE FRACTION IS ENRICHED IN BTK MUTATIONS AND ANTICIPATES RELAPSE IN IBRUTINIB-TREATED CLL
por: Pozzo, Federico, et al.
Publicado: (2023)

Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
por: Zhang, Jing, et al.
Publicado: (2022)

Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition
por: Pepper, C, et al.
Publicado: (2015)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
por: Kueffer, Lauren E., et al.
Publicado: (2021)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

Acidosis Sensing Receptor GPR65 Correlates with Anti-Apoptotic Bcl-2 Family Member Expression in CLL Cells: Potential Implications for the CLL Microenvironment
por: Rosko, Ashley E, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_p8jtlbhoina56i0ebtfq8g9if1